For comparison, three other peptides, Arg-Gly-Asp (RGD), HER-2, and TAT peptides with similarly ~2–3 decades since their discovery [54,55,56], have been extensively studied for active targeting against lung cancer. The gene discussed is ERBB2; the disease is lung carcinoma.